Analyzing Medical Device Impact: Conjoint Analysis & Vignettes

Incorporating healthcare providers’ perspectives in the clinical development process is important for delivering medical devices, diagnostics and pharmaceuticals with high levels of clinical utility. Well-designed healthcare preference studies with vignette-based profiles can demonstrate clinical utility in a cost-effective, time-efficient and robust manner. These studies address many questions for innovators planning to launch successful products, including the following:

• Which characteristics (attributes) of patients or medical products are most important for physicians making decisions regarding diagnosis and treatment?
• What is the relative magnitude of each attribute’s importance in physician decision-making?
• What is the impact of patient characteristics and medical product attributes on physician decision-making?
• Would physicians change their medical recommendations to align with patient management guidelines if they had access to the medical product?

In this webinar, the speaker will discuss the methods used to demonstrate the clinical utility of medical products, and will explain how preference studies, such as conjoint analyses with physician survey data, fit into the armamentarium of techniques used to generate clinical utility evidence. They will provide an overview of conjoint analysis and describe the process of conducting a conjoint analysis study.

The speaker will present a case study showing how conjoint analysis assessed the clinical utility of a blood-based biomarker test that predicts the risk of kidney disease/decline in Type 2 diabetes mellitus patients. This case study will present typical results of a clinical utility study with conjoint analysis: 1) the relative importance of patient/test attributes for physician monitoring, prescribing and dosing decisions; 2) odds ratios for the impact of low-risk, moderate-risk and high-risk test results on physician decision-making; and 3) value messages supported by the study results.

Lastly, the speaker will demonstrate that with conjoint analysis they were able to:

• Quantify the clinically and statistically significant impact of the novel blood-based biomarker test on patient management decisions.
• Objectively demonstrate the test’s value to physicians across a range of patient types by evaluating the relative importance of the blood-based biomarker test’s results compared with standard-of-care test results and other clinical factors.

Who Should Attend:

• Market Access
• Payer Strategy/Value Strategy
• Health Economics
• Outcomes Research
• Advanced Diagnostics

What You Will Learn

Attendees will:

• Understand how conjoint analysis with efficient large sample survey data can inform evidence development plans for medical device, diagnostic and therapeutic companies.
• Learn about the process of conducting a conjoint analysis study to demonstrate clinical utility to payers and healthcare providers.
• View a case study that demonstrates how conjoint analysis assessed the clinical utility of a test predicting the risk of kidney disease/decline in Type 2 diabetes mellitus patients.